Registry for Korean patients with borderline ovarian tumors
Establishing the Registry of Korean Patients With Borderline Ovarian Tumors
This study is collecting information from Korean patients with borderline ovarian tumors to better understand their condition and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | Female |
| Sponsor | Kangbuk Samsung Hospital Academic / other |
| Locations | 4 sites (Changwon and 3 other locations) |
| Trial ID | NCT02803970 on ClinicalTrials.gov |
What this trial studies
This registry aims to collect comprehensive data on Korean patients diagnosed with borderline ovarian tumors (BOTs). Researchers will retrospectively gather information from medical records of patients treated between November 1994 and February 2015, and prospectively collect data from patients treated since March 2015. The data will include various clinical parameters such as age, body mass index, and treatment outcomes, which will be updated every six months to monitor disease progression and follow-up care. This initiative seeks to enhance understanding and management of BOTs in the Korean population.
Who should consider this trial
Good fit: Ideal candidates for this registry are Korean patients diagnosed with borderline ovarian tumors who have undergone treatment and follow-up care.
Not a fit: Patients who did not receive primary treatment or follow-up for at least six months at the participating institutions may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could improve the understanding and treatment of borderline ovarian tumors, leading to better patient outcomes.
How similar studies have performed: While this registry approach is not novel, similar studies have successfully collected data to improve patient care in other regions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea. * All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015 Exclusion Criteria: * Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis
Where this trial is running
Changwon and 3 other locations
- Samsung Changwon Hospital — Changwon, South Korea (Recruiting)
- Kangbuk Samsung Hospital — Seoul, South Korea (Recruiting)
- CHA Gangnam Medical Center — Seoul, South Korea (Recruiting)
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Taejong Song, MD, PhD — Kangbuk Samsung Hospital
- Study coordinator: Taejong Song, MD,PhD
- Email: taejong.song@gmail.com
- Phone: 82-2-2001-2582
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.